1-[2-(1H-吡咯)乙基]哌嗪 | 688763-20-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-[2-(1H-吡咯)乙基]哌嗪
• 英文名称: 1-(2-Pyrrol-1-yl-ethyl)piperazine
• 英文别名: 1-(2-pyrrol-1-ylethyl)piperazine
• CAS: 688763-20-4
• 化学式: C₁₀H₁₇N₃
• 分子量: 179.26
• InChiKey: JEDZVCLTESTPSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933990090
• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  3-(7-Chloro-1-oxo-1,3-dihydro-isoindol-2-yl)-N-[2-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)ethyl]-benzamide 、 1-[2-(1H-吡咯)乙基]哌嗪 、 3-(7-氯-1-氧代异吲哚啉-2-基)苯甲酸 生成 7-chloro-2-{3-[4-(2-pyrrol-1-yl-ethyl)-piperazine-1-carbonyl]-phenyl}-2,3-dihydro-isoindol-1-one
  参考文献：
  名称：

  Novel compounds useful for bradykinin B1 receptor antagonism

  摘要：

  本发明涉及一种能够拮抗缓激肽B1受体的化合物，该化合物可用于治疗哺乳动物中由缓激肽B1受体介导的疾病或缓解与疾病状况相关的不良症状。

  公开号：

  US20070032475A1

文献信息

• Substituted N-heterocyclic Compounds and Their Use as Dopamine D3 Receptor Ligands
  申请人：Geneste Herve

  公开号：US20090054449A1

  公开（公告）日：2009-02-26

  The invention relates to substituted N-heterocyclic compounds of general formula (I.A) and to the tautomers of the compounds the physiologically acceptable salts of the compounds and the physiologically acceptable salts of the tautomers of the compounds. The invention also relates to the use of these compounds and their pharmacologically acceptable salts in the production of a pharmaceutical agent for treating diseases that respond to the influence exerted by dopamine D 3 receptor ligands, especially for treating diseases of the central nervous system, especially schizophrenia and/or depression.

  本发明涉及一般式（I.A）的取代N-杂环化合物，以及该化合物的互变异构体、该化合物的生理上可接受的盐和该化合物的互变异构体的生理上可接受的盐。本发明还涉及使用这些化合物及其药理学上可接受的盐制备用于治疗对多巴胺D3受体配体产生影响的疾病的药物，特别是用于治疗中枢神经系统疾病，特别是精神分裂症和/或抑郁症。
• Pteridine derivatives useful for making pharmaceutical compositions
  申请人：Waer Jozef Albert Mark

  公开号：US20070032477A1

  公开（公告）日：2007-02-08

  This invention relates to a group of substituted pteridine derivatives, their pharmaceutically acceptable salts, N-oxides, solvates, dihydro- and tetrahydro-derivatives, and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular which are highly active immunosuppressive agents, and as such are useful in the treatment in transplant rejection and/or in the treatment of certain inflammatory diseases. These derivatives are also useful in preventing or treating cardiovascular disorders, allergic conditions, disorders of the central nervous system, TNF-α related disorders, viral diseases, inflammatory bowel diseases and cell proliferative disorders.

  本发明涉及一类取代的喹噁啉衍生物，其药学上可接受的盐、N-氧化物、溶剂合物、二氢和四氢衍生物以及对映体，具有出乎意料的理想药理特性，尤其是高活性的免疫抑制剂，因此在移植排斥和/或某些炎症性疾病的治疗中非常有用。这些衍生物还可用于预防或治疗心血管疾病、过敏性疾病、中枢神经系统疾病、TNF-α相关疾病、病毒性疾病、炎症性肠病和细胞增殖性疾病。
• Substituted indole ligands for the ORL-1 receptor
  申请人：Ronzoni Silvano

  公开号：US20090275555A1

  公开（公告）日：2009-11-05

  New ligands for the ORL-1 receptor are described, useful for antagonising the activity of said receptors in a patient in need thereof, and for preventing and treating illnesses dependent on the activation of this receptor. The new compounds conform to structural formula (I) wherein R1, R2, R3, R4 are further defined in the description.

  本文描述了ORL-1受体的新配体，可用于拮抗需要该受体活性的患者，并用于预防和治疗依赖于该受体激活的疾病。新化合物符合结构式（I），其中R1，R2，R3，R4在描述中进一步定义。
• Chemical mechanical planarization for tungsten-containing substrates
  申请人：AIR PRODUCTS AND CHEMICALS, INC.

  公开号：EP2779217A2

  公开（公告）日：2014-09-17

  Chemical mechanical polishing (CMP) compositions for polishing tungsten or tungsten-containing substrates comprise an abrasive, at least one solid catalyst, a chemical additive selected from the groups consisting of piperazine derivatives, salts of cyanate, and combinations thereof; and a liquid carrier. Systems and processes use the aqueous formulations for polishing tungsten or tungsten-containing substrates.

  用于抛光钨或含钨基材的化学机械抛光（CMP）组合物包括磨料、至少一种固体催化剂、一种选自哌嗪衍生物、氰酸盐及其组合的化学添加剂；以及一种液体载体。系统和工艺使用水性制剂抛光钨或含钨基材。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS RAF INHIBITORS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1432702B1

  公开（公告）日：2006-08-16